Nimbus
Discovery is applying advances in computer-based drug discovery to develop new
medicines against important drug targets and thereby unlock fundamental
biological pathways. Nimbus has established a first-of-its-kind partnership
with Schrödinger, the leader in computational drug discovery, to gain
privileged access to cutting-edge technology and exclusive rights to key
targets. Nimbus has identified selective, potent, and differentiated compounds
for two disease targets, ACC and IRAK4, that are pivotal in the areas of
immunology, obesity, and oncology.
Other Investors include Atlas Ventures, SR One, and Gates
Ventures.